| Home Market Dynamics You and Market Sector Analysis Company Insights AI Investing About Contact Us Login |
| The price action of Biotechnology (IBB) sector is shaped by numerous forces, ranging from broad macroeconomic trends to company-specific performance and market structure. The overall sentiment for Biotechnology sector is very positive (overall 2.8, positive 4.3, negative -1.5) on 20251031. The forces of Sentiment towards Fundamentals (2), Sector Price Trend (1), Option Speculation (0.75), Broad Market Trend (0.5), and Market Risk Prefrence (0) will drive up the price. The forces of Price Level (-0.5), and Valuation Sentiment (-1) will drive down the price. 'Buy the dips' is the preferred trading strategy. Hourly SMA 20 trend line is likely to provide a support from any pullbacks. The swing to upside will be significant considering the high positive sentiment forces (4.3). The sentiment for Broad Market Trend is calculated based on SPY trend. The sentiment for Sector Price Trend is calculated based on IBB trend. The sentiment for Option Speculation is calculated from put/call ratio. The Risk Prefrence is calculated from Bitcoin price trend. Price Level sentiment is positive when oversold, and negative when overbought. Valuation Sentiment, and Sentimentals towards Fundamentals are extracted from headlines and market commentary. All sentiment scores are normalized on a -10 - +10 scale. |
| Date | Attention | Average Attention | Price | Price Level | Change | SMA10 Trend | Trend Sentiment | Market Sentiment | Fundamentals | News Sentiment |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-10-31 | 1% | 0.4% | 159.38 | 98 | 1.32% | 0.38% | 1 | 2.8 | 2 | 4.5 |
| 2025-10-30 | 0% | 0.3% | 157.31 | 86 | 0.22% | 0.19% | 0.5 | 1.5 | 1.7 | 1 |
| 2025-10-29 | 0% | 0.3% | 156.97 | 86 | -0.44% | 0.26% | 0.7 | 3.8 | 1.9 | 0 |
| 2025-10-28 | 0% | 0.3% | 157.66 | 96 | 0.35% | 0.39% | 0.6 | 1.9 | 0.6 | 7.7 |
| 2025-10-27 | 1% | 0.3% | 157.11 | 90 | 1.26% | 0.45% | 1.6 | 1.6 | -0.5 | 4 |
| 2025-10-26 | 1% | 0.1% | 0.4 | -0 | 0 | 7 | ||||
| 2025-10-25 | 0% | 0% | 0.4 | 0.1 | 0.1 | 0 | ||||
| 2025-10-24 | 0% | 0% | 155.16 | 76 | 0.38% | 0.33% | 0.4 | 0.1 | 0.1 | 7 |
| 2025-10-23 | 0% | 0% | 154.58 | 73 | 0.43% | 0.13% | 0.2 | 0.1 | 0.3 | 0 |
| 2025-10-22 | 0% | 0% | 153.92 | 71 | -1.35% | 0.13% | 0.2 | -0.6 | 0.5 | 7 |
| Both emotion scores and sentiment scores are calculated in a -10 - +10 scale. | The price level reaches 100 at Bollinger upper band, and zero at lower band. |
| IBB Behaviors |
| ● Biotechnology (IBB) (13%) is likely to move marginally higher. When the price move is against the technical setup, sentiment and emotion, it's a sign of trend reversal. |
| 1 (8) How Royalty Pharma Prints Cash Without Biotech's Biggest Risks Royalty Pharma's recent deals for promising new therapies highlight its unique and successful strategy of funding blockbuster innovation for long-term growth. (https://www.marketbeat.com/) Fri. Oct 31, 2025 | |
| 2 (5) Biotechnology Sector Update: Stocks and Investments to Watch While many investors focus on semiconductors and AI or the growth sector, one of my Economic Modern Family members has been busy. The Biotech Sector ETF (NASDAQ: IBB), has made new multi-year highs. We cannot say new all-time highs as that was made in 2021 during Covid. However, we can discount that unusual time and […] (https://www.seeitmarket.com/) Fri. Oct 31, 2025 | |
| 3 (5) Pfizer, Novo Nordisk Showdown Could Become Rare Biotech Bidding War The two biotech giants are preparing to square off over a buyout of Avidity. (https://www.thestreet.com/) Fri. Oct 31, 2025 | |
| 4 (0) Illumina Inc. Complete Illumina Inc. stock information by Barron's. View real-time ILMN stock price and news, along with industry-best analysis. (https://www.barrons.com/) Fri. Oct 31, 2025 | |
| 5 (0) Emergent Biosolutions Inc. Complete Emergent Biosolutions Inc. stock information by Barron's. View real-time EBS stock price and news, along with industry-best analysis. (https://www.barrons.com/) Thu. Oct 30, 2025 | |
| 6 (2) Novo, Pfizer Square Off Over Metsera in Obesity-Drug Tussle Novo Nordisk A/S made an unsolicited bid for US biotech firm Metsera Inc., sparking a heated battle with Pfizer Inc. to get their hands on weight-loss treatments that both drugmakers want in order to regain lost ground in the booming market. (https://www.bloomberg.com/) Thu. Oct 30, 2025 | |
About
Contact Us
Copyright ©2025 TheMarketUnfolds. All rights reserved. Denver, Colorado, USA